"O tratamento paliativo e Home Care que a Lar e Sade proporcionou minha esposa, nos meses finais de vida, aps longos anos de sofrimento por cncer de ovrio, foi fundamental para a melhora da qualidade de vida, aps ela ficar refratria aos tratamentos convencionais
Estrogen, progesterone, follicle-stimulating hormone, and luteinizing hormone all undergo significant shifts during this transition
The report projects that sales of orforglipron will reach $16 billion in 2031, whereas retatrutide will produce revenue of $30 billion that year, which includes $10 billion in obesity drug sales and $20 billion in diabetes drug sales
Retrieved March 10, 2026, from 3 Nania, R., (2025, December 23)
The roller coaster ride to the first GLP-1 obesity drug While approved first as a drug for diabetes, very early on in its development, when Knudsen first began work on liraglutide she wondered if the same drug could also be used as a treatment of obesity (Molteni, Chen)
Retatrutide is a triple agonist peptide for laboratory research, activating GLP-1, GIP, and Glucagon receptors
